Literature DB >> 19050443

Endogenous ouabain in cardiovascular function and disease.

Paolo Manunta1, Mara Ferrandi, Giuseppe Bianchi, John M Hamlyn.   

Abstract

An endogenous ouabain has been isolated and conclusively identified from several mammalian tissues, including human plasma, by a number of independent laboratories. Substantial evidence from independent laboratories in several continents is consistent with an adrenal source for most if not all of the circulating endogenous ouabain. Accumulating evidence suggests that circulating levels of endogenous ouabain in humans are modulated by dietary salt and chronic volume status. Endogenous ouabain is linked significantly with vascular function in hypertension and likely impacts the pathogenesis of heart and renal failure. Moreover, the molecular mechanism of endogenous ouabain-linked hypertension involves the sodium pump/sodium-calcium exchange duet. The outstanding analytical issues include the elucidation of distal events in the biosynthetic pathway for endogenous ouabain and identification of molecular mechanisms that regulate its secretion and clearance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19050443     DOI: 10.1097/HJH.0b013e32831cf2c6

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  36 in total

Review 1.  Endogenous ouabain: a link between sodium intake and hypertension.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 2.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 3.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

Review 4.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 5.  Personalized Therapy of Hypertension: the Past and the Future.

Authors:  Paolo Manunta; Mara Ferrandi; Daniele Cusi; Patrizia Ferrari; Jan Staessen; Giuseppe Bianchi
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

6.  Why isn't endogenous ouabain more widely accepted?

Authors:  Mordecai P Blaustein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-03       Impact factor: 4.733

7.  Effect of ouabain on myocardial ultrastructure and cytoskeleton during the development of ventricular hypertrophy.

Authors:  Shao-hua Zhao; Hai-qing Gao; Xiang Ji; Yan Wang; Xiang-ju Liu; Bei-an You; Xiao-pei Cui; Jie Qiu
Journal:  Heart Vessels       Date:  2012-01-13       Impact factor: 2.037

Review 8.  Regulation of renal function and structure by the signaling Na/K-ATPase.

Authors:  Jeffrey X Xie; Xin Li; Zijian Xie
Journal:  IUBMB Life       Date:  2013-12-10       Impact factor: 3.885

Review 9.  Endogenous Ouabain: Recent Advances and Controversies.

Authors:  John M Hamlyn; Mordecai P Blaustein
Journal:  Hypertension       Date:  2016-07-25       Impact factor: 10.190

10.  Low dose ouabain stimulates NaK ATPase α1 subunit association with angiotensin II type 1 receptor in renal proximal tubule cells.

Authors:  Corey J Ketchem; Clayton D Conner; Rebecca D Murray; Madalyn DuPlessis; Eleanor D Lederer; Daniel Wilkey; Michael Merchant; Syed J Khundmiri
Journal:  Biochim Biophys Acta       Date:  2016-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.